Citius Pharmaceuticals Inc Cash Flow Conversion Efficiency
Citius Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.30 Million) by net assets ($69.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Citius Pharmaceuticals Inc (2011–2025)
Cash flow conversion efficiency of Citius Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Citius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Citius Pharmaceuticals Inc stock price for real-time trading data and today's change.
Citius Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Citius Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Citius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Citius Pharmaceuticals Inc (CTXR) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Raptis Group Ltd
AU:RPG
|
0.037x |
|
Neurosense Therapeutics Ltd
NASDAQ:NRSN
|
1.177x |
|
SenzaGen AB
ST:SENZA
|
-0.052x |
|
InfoBank Corporation
KQ:039290
|
-0.003x |
|
Freeport Resources Inc
V:FRI
|
-0.408x |
|
West Coast Silver Ltd
AU:WCE
|
-1.634x |
|
FORIS AG
F:FRS
|
-0.097x |
|
Konsolidator AS
CO:KONSOL
|
0.165x |
Annual Cash Flow Conversion Efficiency for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Citius Pharmaceuticals Inc from 2011 to 2025. Review Citius Pharmaceuticals Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $77.53 Million | $-26.55 Million | -0.342x | +10.01% |
| 2024-09-30 | $74.10 Million | $-28.20 Million | -0.381x | -19.74% |
| 2023-09-30 | $91.43 Million | $-29.06 Million | -0.318x | -15.91% |
| 2022-09-30 | $103.43 Million | $-28.36 Million | -0.274x | -50.15% |
| 2021-09-30 | $132.78 Million | $-24.25 Million | -0.183x | +63.68% |
| 2020-09-30 | $33.67 Million | $-16.93 Million | -0.503x | +1.44% |
| 2019-09-30 | $24.38 Million | $-12.44 Million | -0.510x | -25.61% |
| 2018-09-30 | $27.87 Million | $-11.32 Million | -0.406x | -11.83% |
| 2017-09-30 | $21.95 Million | $-7.97 Million | -0.363x | -3.20% |
| 2016-09-30 | $16.77 Million | $-5.90 Million | -0.352x | -109.37% |
| 2015-09-30 | $-635.21K | $-2.39 Million | 3.755x | +295.18% |
| 2014-09-30 | $-741.93K | $-705.05K | 0.950x | +530.18% |
| 2013-09-30 | $93.27K | $-20.60K | -0.221x | -149.83% |
| 2012-09-30 | $-45.85K | $-20.32K | 0.443x | -49.14% |
| 2011-09-30 | $-23.84K | $-20.78K | 0.872x | -- |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more